As of 18 May 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of gadobutrol (1) 1.0 mmol/mL solution for injection, 7.5 mL, in a clear colorless glass vial and (2) 1.0 mmol/mL solution for IV infusion, 7.5 mL in a type 1 colorless glass pre-filled syringe (PFS) for use in diagnostic magnetic resonance imaging (MRI) in adults and children. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 18 May (Monday) to 01 June (Monday) 2026.

As a preliminary recommendation, the HTA Council recommends the government financing of the following:

• Gadobutrol 1.0 mmol/mL solution for injection, 7.5 mL, in a clear colorless glass vial; and
• Gadobutrol 1.0 mmol/mL solution for IV infusion, 7.5 mL in a type 1 colorless glass pre-filled syringe.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 01 June 2026 (Monday) [EXTENDED until 02 June 2026 (Tuesday)], for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format and those submitted beyond the deadline shall not be entertained.